The birth cohort pattern of decreased H. pylori infection reported in a systematic review contributes to explain the declining GC mortality in Japan. Current trends in estimated annual percentage change of GC incidence foreshadow expected reversals in both falling incidence and male predominance among US non-Hispanic whites.
Combining serum pepsinogen 1 and H. pylori serology was shown to be useful for GC risk stratification in a Finnish population. Gastritis staging by operative link on gastritis assessment was confirmed to be reliable in predicting GC risk in a large prospective study. In a randomized trial from South Korea, H. pylori eradication therapy significantly reduced the rates of metachronous GC in patients who received curative endoscopic resection for early GC. A study based on a territory-wide health care database of the Hong Kong Hospital Authority showed that aspirin use is associated with a reduced GC risk. Another study based on the same database showed that proton pump inhibitors increase GC risk, but methodological biases have most likely acted as confounders. Confirmatory data on the role of endoscopic submucosal dissection in patients with early GC have been published. The phase III FLOT4 trial has shown that the FLOT triplet regimen (docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil) improves the outcome of patients with GC and locoregional disease as compared to the ECF triplet (epirubicin, cisplatin, and 5-fluorouracil). In the phase III ATTRACTION-2 trial, nivolumab was shown to be an effective treatment option with a relative safe profile for heavily pretreated patients with advanced GC. Current trends foreshadow expected reversals in both falling incidence and male predominance among non-Hispanic whites. Male patients (P = 0.027) and those with incomplete IM (P = 0.001)
| G A S TRI C C AN CER : EPIDEMI OLOG I C AL A S PEC TS
were at greatest risk of developing dysplasia or early GC. There was also a trend toward an association with smoking (P = 0.08). The authors concluded that further studies are required for determining optimal surveillance intervals to reduce GC incidence and mortality.
To evaluate the prevalence and the long-term course of gastric precancerous lesions in patients with gastric MALT-lymphoma (GML), records of patients with GML (N = 179), gastric diffuse large B-cell lymphoma (N = 70), and H. pylori gastritis (N = 152), from a single-center from January 1995 to January 2014 were retrospectively evaluated. 5 At baseline, gastric atrophy was more frequent in the GML group. Furthermore, in patients with GML, gastric atrophy, IM, and gastric dysplasia were more frequent in the GML area than in other part of the stomach. During follow-up, the prevalence of gastric atrophy remained stable whereas IM and dysplasia tended to increase over time. In the multivariate analysis, the development of dysplasia or GC was associated with the presence of IM at baseline and male gender. Thus, after achieving complete remission, GML patients with gastric precancerous lesions may benefit from endoscopic surveillance.
| G A S TRI C C AN CER : PRE VENTI ON S TR ATEG IE S/SCREENING FOR PRENEOPL A S TIC CONDITIONS
Serum pepsinogen 1 (PG1) and H. pylori serology are useful tools for GC risk stratification in Asia. Testing the sera of Finnish male smokers from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Song et al 6 were also able to show the usefulness of these markers in the Finnish population. PG1 measurements were available for 21 895 study participants. In a subset (N = 3555) with H. pylori positive serology, both markers jointly defined four groups: the normal PG1 groups A (H. pylori-negative) and B (H. pylori-positive) and the low PG1 groups C (H. pylori-positive) and D (H. pylori-negative).
Overall, 329 GCs were diagnosed with an average of 13.9 years after baseline. Low PG1 at baseline was associated with a roughly three- restaging, whereas those with stages 0 and I were followed clinically.
At baseline, the majority of patients had stage 0 (77.6%), whereas In a prospective, double-blind, placebo-controlled, randomized trial, 470 patients from South Korea who had undergone endoscopic resection of early GC or high grade adenoma were assigned to receive either H. pylori eradication therapy with antibiotics (amoxicillin 1000 mg and clarithromycin 500 mg twice daily for 7 days) or placebo. 8 Furthermore, the PPI rabeprazole (10 mg twice daily) was given and maintained in both groups for an additional 4 weeks to promote ulcer healing. Two primary outcomes were the incidence of between aspirin and non-aspirin use was modest to low (2.52 fewer GCs per 10 000 person-years). As aspirin is also a major cause of gastrointestinal bleeding, the risk-benefit profile of aspirin use on GC prevention has yet to be defined. The benefit of aspirin use on GC prevention may be highest among patients with advanced preneoplastic conditions (ie, gastric atrophy, IM) whereas in the absence of preneoplastic changes of the gastric mucosa, no further benefit is expected after H. pylori eradication.
PPI use is associated with worsening of gastric atrophy, particu- 
| G A S TRI C C AN CER : TRE ATMENT
Confirmatory data on the role of endoscopic submucosal dissection (ESD) in patients with early GC were published in the last year. In a 10.9%, 95% CI 6.2-17.0 for nivolumab and placebo, respectively).
Thus, nivolumab might be a new treatment option with a relative safe profile for heavily pretreated patients with advanced GC and AEG.
| CON CLUS IONS
The epidemiology of GC is changing. The birth cohort effect observed for H. pylori infection explains, at least in part, the declining GC mortality in Japan whereas the causal mechanisms responsible for the increasing GC incidence among younger women in the United States need to be unraveled. New evidence supports the usefulness of serological (Pepsinogen I) and histomorphological biomarkers (OLGA staging system) for stratifying GC risk. H. pylori eradication therapy reduces but does not abolish the rate of metachronous GC in patients undergoing endoscopic resection for early GC. Whether regular aspirin use may be an alternative to follow-up endoscopy in these high risk patients has still to be determined. More data has been gained on the role of ESD in patients with early GC. The triplet FLOT can be considered the new standard of care in the perioperative treatment of patients with resectable GC or AEG, whereas nivolumab represents a new treatment option with a relative safe profile for heavily pretreated patients with advanced GC and AEG. 
D I S CLOS U R E O F I NTE R E S T S

R E FE R E N C E S
